Nuzenio

Modzatinib

Modzatinib entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 2 latest news signals 2 publisher sources 100/100 entity strength

Latest news

US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology DigestThe Dermatology Digest · Fri, 07 Aug 2026 15:34:47 GMT Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:35:00 GMT

Timeline

Fri, 07 Aug 2026 15:34:47 GMTUS FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest

Thu, 06 Aug 2026 20:35:00 GMTAclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo Finance

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

US FDA Fast2 live mentions Aclaris2 live mentions ATI2 live mentions Moderate2 live mentions Severe Lichen Planus2 live mentions Lichen Planus1 live mentions The Dermatology Digest1 live mentions Lichen Planus The1 live mentions Dermatology Digest The1 live mentions Dermatology Digest1 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Modzatinib.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.